Switch to:

Denali Therapeutics Cash Flow from Operations

: $-10.7 Mil (TTM As of Sep. 2019)
View and export this data going back to 2017. Start your Free Trial

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Sep. 2019, Denali Therapeutics's Net Income From Continuing Operations was $-46.3 Mil. Its Depreciation, Depletion and Amortization was $1.9 Mil. Its Change In Working Capital was $6.4 Mil. Its cash flow from deferred tax was $0.0 Mil. Its Cash Flow from Discontinued Operations was $0.0 Mil. Its Stock Based Compensation was $8.9 Mil. And its Cash Flow from Others was $-1.4 Mil. In all, Denali Therapeutics's Cash Flow from Operations for the three months ended in Sep. 2019 was $-30.4 Mil.


Denali Therapeutics Cash Flow from Operations Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Denali Therapeutics Annual Data
Dec15 Dec16 Dec17 Dec18
Cash Flow from Operations -15.05 -71.91 -76.64 50.12

Denali Therapeutics Quarterly Data
Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cash Flow from Operations Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.82 93.19 -30.32 -43.18 -30.44

Denali Therapeutics Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

's Cash Flow from Operations for the fiscal year that ended in Dec. 2018 is calculated as:

Denali Therapeutics's Cash Flow from Operations for the quarter that ended in Sep. 2019 is

Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2019 was 93.185 (Dec. 2018 ) + -30.323 (Mar. 2019 ) + -43.175 (Jun. 2019 ) + -30.435 (Sep. 2019 ) = $-10.7 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Denali Therapeutics  (NAS:DNLI) Cash Flow from Operations Explanation

Cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Denali Therapeutics's net income from continuing operations for the three months ended in Sep. 2019 was $-46.3 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Denali Therapeutics's depreciation, depletion and amortization for the three months ended in Sep. 2019 was $1.9 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Denali Therapeutics's change in working capital for the three months ended in Sep. 2019 was $6.4 Mil. It means Denali Therapeutics's working capital increased by $6.4 Mil from Jun. 2019 to Sep. 2019 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Denali Therapeutics's cash flow from deferred tax for the three months ended in Sep. 2019 was $0.0 Mil.

5. Cash Flow from Discontinued Operations:
Cash received by a company that comes from the sale of part of business.

Denali Therapeutics's cash flow from discontinued operations for the three months ended in Sep. 2019 was $0.0 Mil.

6. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Denali Therapeutics's stock based compensation for the three months ended in Sep. 2019 was $8.9 Mil.

7. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Denali Therapeutics's cash flow from others for the three months ended in Sep. 2019 was $-1.4 Mil.


Denali Therapeutics Cash Flow from Operations Related Terms


Denali Therapeutics Cash Flow from Operations Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)